Yantai Dongcheng Pharmaceutical Group Co Ltd (002675):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Yantai Dongcheng Pharmaceutical Group Co Ltd (002675) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9421
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Yantai Dongcheng Pharmaceutical Group Co Ltd (Yantai Dongcheng Pharma), formerly Yantai Dongcheng Biochemicals Co Ltd, is a developer, manufacturer, and marketer of biochemical API, chemical synthetic drugs, and Chinese medicines. The company offers its products under categories including heparin series, chondroitin sulfate series, marine collagen, hyaluronic acid, glucosamine series, heparinoid and cytochrome C. It provides its products for various therapeutic indications such as cardiovascular, oncology, orthopedics, and anti-infection. Yantai Dongcheng Pharma exports its products globally. The company operates its subsidiaries in China and the US. Yantai Dongcheng Pharma is headquartered in Yantai, China.

Yantai Dongcheng Pharmaceutical Group Co Ltd (002675) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Yantai Dongcheng Biochemicals Raises USD58.4 Million in Private Placement of Shares 10
Yantai Dongcheng Biochemicals Completes IPO For US$111 Million 11
Acquisition 13
Yantai Dongcheng Plans to Acquire 70% Stake in Biological Products Company for USD48.4 Million 13
Yantai Dongcheng Plans to Acquire 83.5% Stake in Pharmaceutical Company for USD10 Million 14
Yantai Dongcheng Pharmaceutical Group Co Ltd – Key Competitors 15
Yantai Dongcheng Pharmaceutical Group Co Ltd – Key Employees 16
Yantai Dongcheng Pharmaceutical Group Co Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Yantai Dongcheng Pharmaceutical Group Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Yantai Dongcheng Biochemicals Raises USD58.4 Million in Private Placement of Shares 10
Yantai Dongcheng Biochemicals Completes IPO For US$111 Million 11
Yantai Dongcheng Plans to Acquire 70% Stake in Biological Products Company for USD48.4 Million 13
Yantai Dongcheng Plans to Acquire 83.5% Stake in Pharmaceutical Company for USD10 Million 14
Yantai Dongcheng Pharmaceutical Group Co Ltd, Key Competitors 15
Yantai Dongcheng Pharmaceutical Group Co Ltd, Key Employees 16
Yantai Dongcheng Pharmaceutical Group Co Ltd, Subsidiaries 17

List of Figures
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Yantai Dongcheng Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Yantai Dongcheng Pharmaceutical Group Co Ltd (002675):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Allergan Plc (AGN):企業の財務・戦略的SWOT分析
    Allergan Plc (AGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Caldera Health Ltd:企業の製品パイプライン分析2018
    Summary Caldera Health Ltd (Caldera) is a biotech company that develops prostate cancer diagnostic tools. The company offers prostate cancer diagnostic and prognostic tests to detect and monitor the cancer disease. It has developed a laboratory test that measures the expression of a range of RNA bio …
  • Uponor Oyj:企業の戦略・SWOT・財務情報
    Uponor Oyj - Strategy, SWOT and Corporate Finance Report Summary Uponor Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Galmed Pharmaceuticals Ltd (GLMD):製薬・医療:M&Aディール及び事業提携情報
    Summary Galmed Pharmaceuticals Ltd (Galmed Pharmaceuticals), a subsidiary of Galmed International Ltd, is a clinical-stage biopharmaceutical company. The company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST …
  • Saertex GmbH & Co KG:企業の戦略的SWOT分析
    Saertex GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • TMRC Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TMRC Co Ltd (TMRC) is a biopharmaceutical company that develops and markets anti-cancer and cancer related products. The company’s products include tamibarotene Am-80, TOS-80T, OMS0728, and others. Its tamibarotene is a synthetic retinoid, which is designed to develop drug-able properties of …
  • Solent NHS Trust:企業の戦略的SWOT分析
    Solent NHS Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Obalon Therapeutics Inc (OBLN):医療機器:M&Aディール及び事業提携情報
    Summary Obalon Therapeutics Inc (Obalon Therapeutics) is a manufacturer of medical devices and equipment. The company offers development and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It also researches, designs, produces, and sells medical gast …
  • RBC Wealth Management:企業の戦略・SWOT・財務情報
    RBC Wealth Management - Strategy, SWOT and Corporate Finance Report Summary RBC Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Mytilineos Holdings Sa
    Mytilineos Holdings Sa - Strategy, SWOT and Corporate Finance Report Summary Mytilineos Holdings Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Golden Ocean Group Limited:企業のM&A・事業提携・投資動向
    Golden Ocean Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Golden Ocean Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Gerresheimer AG:戦略・SWOT・企業財務分析
    Gerresheimer AG - Strategy, SWOT and Corporate Finance Report Summary Gerresheimer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Atossa Genetics Inc:企業のM&A・事業提携・投資動向
    Atossa Genetics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Atossa Genetics Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Virgin Group Ltd.:企業の戦略・SWOT・財務分析
    Virgin Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Virgin Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Al-Nisr Al Arabi Insurance Company:企業の戦略・SWOT・財務情報
    Al-Nisr Al Arabi Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Al-Nisr Al Arabi Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • Centrais Eletricas Brasileiras S.A. (ELET6):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas Brasileiras S.A. (Eletrobras) is an electric utility. It generates, transmits, and distributes energy. The company produces electricity from hydro, nuclear, wind, natural gas, oil, coal, solar, and biomass sources. Eletrobras promotes the Latin American electric integratio …
  • Tulmar Safety Systems Inc.:企業の戦略・SWOT・財務分析
    Tulmar Safety Systems Inc. - Strategy, SWOT and Corporate Finance Report Summary Tulmar Safety Systems Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Misen Energy AB (MISE):企業の財務・戦略的SWOT分析
    Summary Misen Energy AB (Misen) is an oil and gas company that provides pipeline services. The company offers production of gas and oil fields by implementation of large-scale investment programs and introduction of modern western knowhow and technology. It provides development of new and redevelopm …
  • Rockwool International AS:戦略・SWOT・企業財務分析
    Rockwool International AS - Strategy, SWOT and Corporate Finance Report Summary Rockwool International AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆